[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345039-105":59,"doc-detail-345039-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cereblon-crbn-inhibits-prostate-cancer-metastasis-by-negatively-regulating-6-phosphogluconate-dehydrogenase-6pgd","Cereblon (CRBN) inhibits prostate cancer metastasis by negatively regulating 6-phosphogluconate dehydrogenase (6PGD)","","Metastasis drives mortality in advanced prostate cancer, while resistance to androgen receptor–targeted therapies creates an urgent need for new treatments. This study identifies cereblon (CRBN), a CRL4CRBN substrate receptor, as a tumor-suppressive regulator of prostate cancer metastasis via control of 6-phosphogluconate dehydrogenase (6PGD), a key oxidative pentose phosphate pathway enzyme. CRBN directly binds 6PGD and promotes ubiquitination and proteasomal degradation, lowering NADPH/NADP+ and suppressing migration, invasion, and EMT-like transcriptional programs. Loss of CRBN stabilizes 6PGD and reverses these effects, while 6PGD inhibition restores CRBN-driven phenotypes. In mouse xenografts, CRBN reduces metastatic dissemination, supporting CRBN–6PGD as a metabolic checkpoint and a potential therapeutic axis for CRBN-deficient or 6PGD-driven cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cereblon-crbn-inhibits-prostate-cancer-metastasis-by-negatively-regulating-6-phosphogluconate-dehydrogenase-6pgd/345039/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cereblon-crbn-inhibits-prostate-cancer-metastasis-by-negatively-regulating-6-phosphogluconate-dehydrogenase-6pgd/345039.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does CRBN affect prostate cancer metastasis in this study?","Question",{"text":112,"@type":113},"CRBN suppresses metastatic dissemination by promoting proteasomal degradation of 6PGD, which reduces NADPH/NADP+ and restrains cell migration and invasion.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the role of 6PGD in the CRBN–6PGD axis?",{"text":117,"@type":113},"6PGD is a critical enzyme in the oxidative pentose phosphate pathway. When stabilized due to CRBN loss, it increases NADPH/NADP+ and supports pro-metastatic behaviors.",{"name":119,"@type":110,"acceptedAnswer":120},"Does CRBN work through direct binding to 6PGD?",{"text":121,"@type":113},"Yes. CRBN directly binds a conserved C-terminal α-helix in 6PGD, leading to polyubiquitination and degradation independently of immunomodulatory drugs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345039,1790122015,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","[www.nature.com/onc](www.nature.com/onc Oncogene)[ Oncogene](www.nature.com/onc Oncogene)  \nARTICLE OPEN   \nCereblon (CRBN) inhibits prostate cancer metastasis by negatively regulating 6-phosphogluconate dehydrogenase (6PGD)  \nKoushik Guchhait 1,11, Hyeon-Seung Yoon1,11, Hyun-Su An1, Seungheon Shin2, Hye Seung Nam1, Francisco D. Yanqui-Rivera 1, Samara M. Oña3, Miguel Á . Mendez3,4, Jong Yeon Hwang5, Daeho Park 1, Chul-Seung Park1, Jee-Young Han6, Doo Yong Chung7, Seokjae Park 8, Eun-Kyoung Kim8, Su-Geun Yang9 and Steve K. Cho 1,2,10 ✉  \n© The Author(s) 2026  \n\n|  | Metastasis is the primary cause of mortality in advanced prostate cancer, and the emergence of resistance to androgen receptor (AR)-targeted therapies highlights the urgent need for alternative therapeutic strategies. Metabolic reprogramming has increasingly been recognized as a key driver of metastatic progression. In this study, we uncover a novel tumor-suppressive role for cereblon (CRBN), a substrate receptor of the CRL4CRBN E3 ubiquitin ligase complex, in modulating prostate cancer metastasis through regulation of 6-phosphogluconate dehydrogenase (6PGD), a critical enzyme in the oxidative pentose phosphate pathway (oxPPP) . CRBN directly binds a conserved C-terminal α-helix in 6PGD, promoting its polyubiquitination and proteasomal degradation independently of immunomodulatory drugs (IMiDs) . Genetic or pharmacological loss of CRBN via CRISPR/Cas9, RNA interference, or PROTAC-mediated degradation stabilized 6PGD and elevated the NADPH/NADP+ ratio. Conversely, re-expression of wild-type CRBN reduced 6PGD levels, restored NADPH/NADP+ ratio, and suppressed cell migration and invasion. Transcriptomic proﬁling revealed CRBN-induced upregulation of CDH1 and downregulation of the EMT marker MMP1, while CRBN degradation produced the opposite pattern—both effects were reversed by 6PGD inhibition. These regulatory effects were conserved across multiple cancer cell lines and observed in CRBN-deﬁcient mouse tissues. Functional studies using intra-splenic xenograft models further demonstrated that CRBN suppresses metastatic dissemination. Collectively, our ﬁndings identify 6PGD as a novel endogenous substrate of CRBN and establish the CRBN–6PGD axis as a critical metabolic checkpoint in prostate cancer metastasis. Therapeutic |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| targeting of this pathway may offer promising strategies for CRBN-deﬁcient or 6PGD-driven cancers. |  |  |\n|  | Oncogene (2026) 45:1234–1246; [https://doi.org/10.1038/s41388-026-03717-9](https://doi.org/10.1038/s41388-026-03717-9) |  |\n|  |  |  |\n\nINTRODUCTION  \nProstate cancer remains a leading cause of cancer-related mortality among men worldwide, with its lethality primarily driven by metastatic progression—the main contributor to treatment failure and death in advanced-stage disease [1–3] . Metastasis is a complex, multistep process whereby cancer cells detach from the primary tumor, invade surrounding tissues, and disseminate via the bloodstream or lymphatic system to form secondary tumors in distant organs such as the bone, liver, and lungs [4, 5] . Despite advances in androgen receptor (AR)-targeted therapies, resistance to these agents remains a formidable clinical challenge, underscoring the need to identify alternative molecular drivers of metastasis and develop effective strategies to suppress cancer cell dissemination.  \nRecent studies have identiﬁed cereblon (CRBN) as a key regulatory protein in cancer biology. As a substrate receptor of the cullin-RING (CRL4CRBN) E3 ubiquitin ligase complex, CRBN mediates the ubiquitin-dependent degradation of diverse cellular targets involved in transcription, DNA repair, and cell cycle control [6–10] . CRBN is best known as the pharmacological target of immunomodulatory drugs (IMiDs), including thalidomide and its analogs, which exert a","cbCaijBKjJhItlHX","https://ap.wps.com/l/cbCaijBKjJhItlHX","pdf",6403267,13,"English","# Introduction\n## Metastasis as a driver of advanced prostate cancer mortality\n## CRBN as an E3 ubiquitin ligase substrate receptor\n## CRBN substrates and mechanistic links to metastasis\n# Article summary (from abstract)","[{\"question\":\"How does CRBN affect prostate cancer metastasis in this study?\",\"answer\":\"CRBN suppresses metastatic dissemination by promoting proteasomal degradation of 6PGD, which reduces NADPH/NADP+ and restrains cell migration and invasion.\"},{\"question\":\"What is the role of 6PGD in the CRBN–6PGD axis?\",\"answer\":\"6PGD is a critical enzyme in the oxidative pentose phosphate pathway. When stabilized due to CRBN loss, it increases NADPH/NADP+ and supports pro-metastatic behaviors.\"},{\"question\":\"Does CRBN work through direct binding to 6PGD?\",\"answer\":\"Yes. CRBN directly binds a conserved C-terminal α-helix in 6PGD, leading to polyubiquitination and degradation independently of immunomodulatory drugs.\"}]","Cereblon (CRBN) inhibits prostate cancer metastasis by negatively regulating 6-phosphogluconate dehydrogenase (6PGD) | PDF",1790056319,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/765328b909afe90d79a7d1198d0224e6.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b6eda1ce495bc6806017be494f68df0.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c6e1bfcbfe1832ae0051f9352125c68.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bad28380480b4ad52877e3d61c7381a7.webp",980,1301]